Chinese Journal of Cancer : Impact Factor & More
eISSN: 1944-446XpISSN: 1000-467X
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Chinese Journal of Cancer
Chinese Journal of Cancer Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Article Processing Charges | GBP 1370 |
| Publication Time | 12 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Chinese Anti-Cancer Association; US Chinese Anti-Cancer Association |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Chinese Journal of Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Chinese Journal of Cancer
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
- 17 Jun 2026
- Cancer Communications
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
- 10 Jun 2026
- Cancer Communications
TGFBR1*6A and Risk for Colorectal Cancer
- 9 Jun 2026
- Cancer Communications
Impact of China\u2019s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs
- 4 Jun 2026
- Cancer Communications
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
- 4 Jun 2026
- Cancer communications (London, England)
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer
- 21 May 2026
- Cancer Communications
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
- 17 Jun 2026
- Cancer Communications
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
- 10 Jun 2026
- Cancer Communications
TGFBR1*6A and Risk for Colorectal Cancer
- 9 Jun 2026
- Cancer Communications
Impact of China\u2019s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs
- 4 Jun 2026
- Cancer Communications
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
- 4 Jun 2026
- Cancer communications (London, England)
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer
- 21 May 2026
- Cancer Communications
FAQs on Chinese Journal of Cancer
How many articles did Chinese Journal of Cancer publish last year? 
What is the eISSN & pISSN for Chinese Journal of Cancer?
Who is the publisher of Chinese Journal of Cancer?
